Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from 4D Molecular Therapeutics ( (FDMT) ) is now available.
On January 22, 2026, 4D Molecular Therapeutics entered into exchange agreements with RA Capital Healthcare Fund and Biotechnology Value Fund under which these investors swapped a total of 6.6 million shares of the company’s common stock for an equal number of pre-funded warrants. As a result of this transaction, the company reported 51,007,874 shares outstanding as of January 23, 2026, excluding 16,935,665 additional shares issuable upon exercise of existing pre-funded warrants that carry a de minimis $0.0001 exercise price and are subject to beneficial ownership caps of 4.99% or 9.99% to limit concentration. The move reshapes the company’s capital structure by shifting a portion of institutional holdings from common stock into pre-funded warrants, potentially providing flexibility around ownership limits and future dilution while relying on a registration exemption under Section 3(a)(9) of the Securities Act for issuance.
The most recent analyst rating on (FDMT) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on 4D Molecular Therapeutics stock, see the FDMT Stock Forecast page.
Spark’s Take on FDMT Stock
According to Spark, TipRanks’ AI Analyst, FDMT is a Neutral.
The score is held down primarily by weak financial performance (large losses and sustained cash burn) and bearish technical trend signals (below major moving averages with negative MACD). Corporate events provide meaningful support via partnership funding and positive clinical readouts, but valuation remains difficult to support given ongoing losses and no dividend data.
To see Spark’s full report on FDMT stock, click here.
More about 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc. operates in the biotechnology sector, focusing on genetic medicine and related therapeutic platforms, with its capital structure supported by institutional healthcare and life sciences investors such as RA Capital Healthcare Fund and Biotechnology Value Fund.
Average Trading Volume: 968,967
Technical Sentiment Signal: Sell
Current Market Cap: $454.8M
Find detailed analytics on FDMT stock on TipRanks’ Stock Analysis page.